



Name of Patient:							
Name of Physician:	Date:						
PSYCHIATRIC SCREENING CHECKLIST							

Depression and potential for suicide have been reported during and after therapy. In some of these patients, depression has subsided with discontinuation of therapy and recurred when isotretinoin therapy was reintroduced. Emotional instability has been reported with isotretinoin.

Psychiatric evaluation should be part of monthly assessment during **Clarus®** therapy. All patients should sign the Patient Information/Consent/Agreement which is available on the **Clarus®** website at http://www.clarusclearprogram.ca/ or by calling the toll-free number at 1-844-596-9526.

If symptoms of depression develop or worsen during treatment, the drug should be discontinued promptly and the patient referred to appropriate psychiatric treatment. The full product monograph and the Consumer Information can be found on the Clarus® website at http://www.clarusclearprogram.ca/ or by calling the toll-free number at 1-844-596-9526.

Prior to prescribing Clarus®, a careful assessment of the patient's mental state should be made, including whether or not the patient has a personal or family history of previous psychiatric illness.

It may be useful for physicians to screen patients prior to prescribing Clarus® and/or monitor patients during Clarus® therapy using available tools. The Patient Health Questionnaire (PHQ-9) is provided as an example in this package. Please be advised that this questionnaire has not been validated specifically for use in patients taking isotretinoin products for treatment of acne. Patient input from the Patient Health Questionnaire (PHQ-9) is meant to provide guidance in assessing your patient's mental health status. This information, along with other clinical information, may be used to modify treatment or make further referrals to a psychiatric consult, upon clinical discretion on a case-by-case basis. Specific management of depression detected through screening is at the discretion of the physician. Other checklists may also be available and appropriate in the physician's professional judgment.

## Patient Health Questionnaire (PHQ-9)\*

		Not at all	Several days	More than half the days	Nearly every day
1.	Over the <u>last 2 weeks</u> , how often have you been bothered by any of the following problems?				
	a. Little interest or pleasure in doing things				
	b. Feeling down, depressed, or hopeless				
	c. Trouble falling/staying asleep, sleeping too much				
	d. Feeling tired or having little energy				
	e. Poor appetite or overeating				
	f. Feeling bad about yourself or that you are a failure or have let yourself or your family down				
	g. Trouble concentrating on things, such as reading the newspaper or watching television.				
	h. Moving or speaking so slowly that other people could have noticed. Or the opposite; being so fidgety or restless that you have been moving around a lot more than usual.				
	i. Thoughts that you would be better off dead or of hurting yourself in some way.				
		Not difficult at all	Somewhat difficult	Very difficult	Extremely difficult
2.	If you checked off any problem on this questionnaire so far, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?				

## PHQ-9 Questionnaire for Depression Scoring and Interpretation Guide For physician use only

Scoring:		Interpreting PHQ-9 Scores			
	ked in a column. Multiply that number by the value indicated luce a total score. The possible range is 0-27. PHQ-9 score.				
Not at all	(#) x 0 =	Minimal depression	0-4	< 4	
Several days	(#) x 1 =	Mild depression	5-9		
More than half the days	(#) x 2 =	Moderate depression	10-14	> 5 - 14	
Nearly every day	(#) x 3 =	Moderately severe depression	15-19		
Total score:		Severe depression	20-27	> 15	

<sup>\*</sup> Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. (http://www.phqscreeners.com/)